Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation
about
CMV in Hematopoietic Stem Cell TransplantationAntifungal Therapy in Hematopoietic Stem Cell Transplant RecipientsHidden killers: human fungal infectionsInvestigating Clinical Issues by Genotyping of Medically Important Fungi: Why and How?Aspergillus citrinoterreus, a new species of section Terrei isolated from samples of patients with nonhematological predisposing conditionsAspergillus galactosaminogalactan mediates adherence to host constituents and conceals hyphal β-glucan from the immune system.In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosisInfections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort StudyImproving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD.Fungal infections in transplant and oncology patients.Invasive fungal infection among hematopoietic stem cell transplantation patients with mechanical ventilation in the intensive care unit.Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphoterEpigenetic regulation of immune cell functions during post-septic immunosuppression.A risk prediction score for invasive mold disease in patients with hematological malignanciesIron homeostasis and the inflammatory responseClinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisInflammatory monocytes orchestrate innate antifungal immunity in the lung.Causes of death in a contemporary cohort of patients with invasive aspergillosisDynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipientsOutcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azolesVoriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).How I treat mucormycosis.The Fungal Exopolysaccharide Galactosaminogalactan Mediates Virulence by Enhancing Resistance to Neutrophil Extracellular Traps.Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort studyEvaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host diseaseInhaled therapeutics for prevention and treatment of pneumoniaInvasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 yearsDiagnostic and therapeutic challenges in a liver transplant recipient with central nervous system invasive aspergillosis.Cryptococcal tongue lesion in a stem cell transplant patient: first reported caseNeutrophil Interactions Stimulate Evasive Hyphal Branching by Aspergillus fumigatus.Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: Data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003-2016).Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation.Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosisDiagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience.
P2860
Q26740385-8EB54631-08D8-4EDC-83E2-1476DD4CD744Q28080147-4E02EA03-DC69-48CB-BD65-5944E5FBD12FQ29617101-3098DE4C-70AD-481C-AB01-5C7E701D3AA5Q29994504-CC6A8ED0-5C67-48EA-9D3F-6086BAFD7037Q30877963-7246F556-4543-4727-935F-48FFB357A0DFQ31129835-82FD02AF-D7FC-4EDB-8B15-B048AFB58262Q33551044-685F5E83-B986-464B-876B-1EDFAF30839DQ33641898-9AD01988-7D34-4700-B7E9-7CEEB8106F28Q33700953-D5802C4A-5612-4A04-A773-EA2D44E03A9CQ33774641-54ABB194-6B7E-4E0E-BA89-29B6DC8B50C1Q33896940-8055398C-838D-447C-A426-4C014D3DF939Q34160396-7B94CE14-68A7-427D-A72D-F023A11D3939Q34315804-B5889487-C93B-4E45-8517-B6598643A7B0Q34974970-344373F9-71B3-42A8-AC26-4F86D52E54E5Q35005712-5ACE209B-B932-49AE-8368-A720B76B07D3Q35024676-AFD339F4-4D3D-48B0-BD30-2B0CEE3F359AQ35026481-F6F63F82-908B-4AFA-BB46-20A788920059Q35026516-381BCF43-1F33-44CA-9ADA-EE8736A35F31Q35105630-28F3A7B4-05C8-4E9D-B1E5-72F8F3E49B41Q35213770-C20BC9AF-3BEA-490C-996C-8C0E0412BAEAQ35544428-56AE6165-6C02-4F7D-A9D3-F153B0FA9286Q35584615-40E2641E-ACC6-402F-886A-F2FBFC9B0444Q35659502-8B9A18E3-6380-4540-814C-6071787B787FQ35672258-3FCF9F99-FA14-45DA-AE4F-C7CB9B05F4C8Q35797637-796CB0EB-4F9B-46B1-8552-53981B15A814Q35817493-4F4ED6E3-3623-47FB-83B0-1D22A7F7C7D9Q35848794-F813F99F-E543-432E-9A3C-151511899D1EQ35881360-3646F48A-FE8D-4E5A-AE19-B0651E390783Q35903189-4E4436D7-9AE8-4A4B-9A40-C237078A4355Q35925366-5291A792-07C3-4F73-9015-48BEB89BB543Q36059278-223AEF52-C324-400A-9A21-305692D9DC09Q36094956-3574D973-CF0E-4DCF-B034-52D7D4D5220DQ36169516-32105280-9DF5-4A1F-B2DA-0C17D0F68F58Q36246329-559DE9B3-AE06-4D1A-9D54-6FE00ED3E19FQ36353240-690F9B2F-48FC-4DA2-ADEC-F6F4329D4D91Q36540732-F5FD4234-6A2F-4789-9154-6CA7F589E3D0Q36560134-2A0BD4BE-D815-4453-AE12-F84A330DC708Q36584655-0137DD47-EE88-424A-91FB-6F390634B910Q36862446-7C90819E-5D38-48EC-A5D9-B3CA5BD2F3B9Q36876327-8BA2B892-BC6E-4C48-87BB-65A508D15D98
P2860
Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Epidemiology of invasive mold ...... to time after transplantation
@ast
Epidemiology of invasive mold ...... to time after transplantation
@en
Epidemiology of invasive mold ...... to time after transplantation
@nl
type
label
Epidemiology of invasive mold ...... to time after transplantation
@ast
Epidemiology of invasive mold ...... to time after transplantation
@en
Epidemiology of invasive mold ...... to time after transplantation
@nl
prefLabel
Epidemiology of invasive mold ...... to time after transplantation
@ast
Epidemiology of invasive mold ...... to time after transplantation
@en
Epidemiology of invasive mold ...... to time after transplantation
@nl
P2860
P3181
P356
P1476
Epidemiology of invasive mold ...... to time after transplantation
@en
P2093
Arlo Upton
Kieren A Marr
P2860
P304
P3181
P356
10.1086/591969
P407
P577
2008-10-01T00:00:00Z